Loading data for ARCT — first visit, this takes a few seconds.
Arcturus Therapeutics In... (ARCT)
NasdaqGM: ARCT
· Real-Time Price · USD
10.28
+2.07 (25.21%)
At close: Aug 27, 2026, 8:00 PM
16.17
+0.00%
After-hours: 5:29 PM
The price, the headline numbers and the latest news, in one place.
Arcturus Therapeutics Inc. (ARCT) Stock Price, Analysis & Data
25.21% (1D)
No data available
| Bid | 4.43 |
| Market Cap | 459.6M |
| Revenue (ttm) | 29.37M |
| Net Income (ttm) | -93.28M |
| 2.27 | |
| -3.33 | |
| n/a | |
| -4.35 | |
| P/B (ttm) | 2.67 |
| P/S (ttm) | 15.65 |
| Earnings Date | n/a |
| Ask | 7.96 |
| Volume | 5,616,094 |
| Avg. Volume (20D) | 577,675 |
| Open | 9.40 |
| Previous Close | 8.21 |
| Day's Range | 9.33 - 11.10 |
| 52-Week Range | 5.50 - 24.17 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which ...
Industry Biotechnology
Sector Healthcare
IPO Date May 22, 2013
Employees 106
Stock Exchange NasdaqGM
Ticker Symbol ARCT
Website https://arcturusrx.com
Financial Performance
In 2025, Arcturus Therapeutics's revenue was 67.22M, a decrease of -51.43% compared to the previous year's 138.39M. Earnings were -65.78M, a decrease of -18.73%.
Financial StatementsEarnings Surprise
Arcturus Therapeutics has released their quarterly earnings on Aug 6, 2026:
- Revenue of $880K misses estimates by $0, with -96.41% YoY decline.
- EPS of -0.84 exceeds estimates by 0.19, with -147.06% YoY decline.
Page 1 of 2